USA flag logo/image

An Official Website of the United States Government

COMBINATORIAL RAT PANELS FOR PHARMACOGENETIC EFFECTS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
60913
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
ES011432
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PHYSIOGENIX, INC.
PHYSIOGENIX, INC. 10437 INNOVATION DR, STE 325 WAUWATOSA, WI 53226-4838
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: COMBINATORIAL RAT PANELS FOR PHARMACOGENETIC EFFECTS
Agency: HHS
Contract: 1R43ES011432-01
Award Amount: $100,000.00
 

Abstract:

This SBIR Phase I project will create and validate a combinatorial panel of rats designed to detect genetic differences to drug response including toxicity. The genome sequencing projects are bringing new molecular tools to both the pharmacologist and toxicologist. However, each species has its own biological foundations that may lead to misclassification on drug toxicity and result in (1) a high failure rate of new compounds late in clinical trials, (2) unnecessary exposure to human subjects, and (3) the inability to detect small subsets of at-risk individuals in heterogeneous human populations. A need exists for animal model systems that reflect the heterogeneity of the human population while maintaining the phenotypic accuracy of an inbred strain. PhysioGenix, Inc. will determine whether new combinatorial panel of rats fulfills these requirements by measuring both the biochemical and genetic effects of two compounds with well-known toxicity profiles. The molecular basis for the variable drug response will be characterized by gene expression profiling utilizing DNA microarray technology. Phase II efforts will expand the test compounds and tissues used, leading to construction of a database knowledge warehouse. PROPOSED COMMERCIAL APPLICATIONS: About $500 million is spent annually to purchase rats for drug discovery and safety testing. Service-based and Pharmaceutical companies will integrate PhysioGenix' combinatorial rat panel into their pre-clinical drug toxicity studies. Research programs directed at either rescuing previously failed drugs or rationally deriving new compounds will incorporate PhysioGenix tools into their study designs.

Principal Investigator:

Steven H. Nye
4147717469
SNYE@PHYSIOGENIX.COM

Business Contact:

Howard Jacob
4143057469
JACOB@MCW.EDU
Small Business Information at Submission:

PHYSIOGENIX, INC.
PHYSIOGENIX, INC. 10437 INNOVATION DR, STE 329 MILWAUKEE, WI 53226

EIN/Tax ID: 391906674
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No